{"ticker": {"uuid": "0ba5c07e-7e9a-46c9-85ea-4189e38e100f", "symbol": "CPIX", "name": "Cumberland Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Cumberland Pharmaceuticals declares $1.50 special dividend, $5M buyback after $100M Apotex deal", "summary": "Cumberland Pharmaceuticals (CPIX) announced a special cash dividend of $1.50 per share and a new $5 million share repurchase program. These actions follow the closing of a $100 million strategic transaction with Apotex, which provided additional net cash. The company stated that ", "url": "https://www.tradingview.com/news/tradingview:9ee27ebfda661:0-cumberland-pharmaceuticals-declares-1-50-special-dividend-5m-buyback-after-100m-apotex-deal/", "source_name": "TradingView", "published_at": "2026-07-14T03:34:38", "published_display": "14 Jul 2026 03:34", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals 8-K Filing July 2026: Key Company Details, Stock Info, and Address on NASDAQ CPIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPcndoQkNIMWdfV0pIU0lJMnJHOF91Q3dHZ2w5WnNMeG82aVh1aHlkTTgtM2hkNXMtSDJhNEotbTFzUWJZeURFSDROaTJEWUNObTZGWnNsanRZZmZzbnZkM1lKSTZqR0s1d0V3VzloLVo2bUZxZDJ1czUzZUdIcThMTEZER2RNTEdVNlJqWDFQdlVHeDY3QWRqQ3UzaFJSbWE0bENEWlBiVTgxa3ZJLURBNGZBNFRsckt0dG5qTjlPQ09fS2JtZmV1NmtHU041UG9meGpUeUI5WDBuV0tvZWhJ?oc=5", "source_name": "Minichart", "published_at": "2026-07-14T00:44:00+00:00", "published_display": "14 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (Nasdaq: CPIX) returns cash after $100M Apotex deal", "summary": "Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share and authorized a new $5 million share repurchase program. These actions follow the company's strategic transaction with Apotex Health Corp., which brought in $100 million in cash at closing and ", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-52aff2944a9f.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:40:38", "published_display": "13 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals declares $1.50 dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZm5hUTBiTXpNWnlQTks0Q3Y3UnpacTA1ZUJsYmdHTkxTdEVGVzBWZDJGN0FIU2d5TmlWMjQxR2xtV3F3MF9BZGxOUGNDMkpfM3ZrYlJraVlGZWU1ZmhudFNyT1J3SHB2X19qVXNJZmN5MUcxYmdwS0QxcGo2SkFPbG1UUmczS2tjNW01UC0wcnNNZVVuWjFUVVMtdDlhNDFGbTBkUzJyNHpKZw?oc=5", "source_name": "MSN", "published_at": "2026-07-13T20:35:26+00:00", "published_display": "13 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX", "summary": "Cumberland Pharmaceuticals Inc.'s board of directors has authorized and declared a special cash dividend of $1.50 per share of common stock. This dividend will be payable on August 9, 2026, to shareholders of record as of July 26, 2026. The special dividend reflects the company's", "url": "https://www.moomoo.com/news/post/72869066/cumberland-pharma-board-of-directors-has-authorized-and-declared-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T16:40:38", "published_display": "13 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Declares Special Dividend, Approves $5 Million Share Buyback", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cumberland-declares-special-dividend-approves-152645804.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:26:45+00:00", "published_display": "13 Jul 2026 15:26", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQNmJSMWJJOTBUVTRrYnlXc0YxUEcxWGtfdjVjMy1jUnlwR0sxLWhEc3UxSU03X0NRQVpzcGNySjVERUFXWFIyM25YYWljeTVQdWQ2b0ROZDlPa1FlOGtiWkdfWURRb3ZMXzhwZlRWNlVkckRySHZQU0VxM2dmbU1HWkNPYlpjQkk3NFhNMEctSGV0NWdrM25sc2NRM212eXMzN0ctc1ViaHZXcXJtTU1YLVdVa2w?oc=5", "source_name": "Market source", "published_at": "2026-07-13T15:20:00+00:00", "published_display": "13 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE", "summary": "Cumberland Pharmaceuticals has announced a special cash dividend of $1.50 per common share. This dividend is payable to shareholders of record as of July 29, 2026, with the payment scheduled for August 12, 2026. This announcement highlights the company's financial performance and", "url": "https://www.moomoo.com/news/post/72869053/press-release-cumberland-pharmaceuticals-announces-special-dividend-of-1-50?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:40:38", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced a special cash dividend of $1.50 per share following a strategic transaction with Apotex Health. The dividend will be payable on July 31, 2026, to shareholders of record on July 10, 2026. This decision, along with a $5 mill", "url": "https://www.tradingview.com/news/prnewswire:cf16d7aeb8911:0-cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-share/", "source_name": "TradingView", "published_at": "2026-07-13T14:45:45", "published_display": "13 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$1.50-a-share cash windfall as Cumberland pivots to rare-disease drug ifetroban", "summary": "Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026, following a strategic transaction with Apotex Health that provided $100 million in cash. The company also authorized a $5 million share repurchase program and will red", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-zx3mc7ddqelp.html", "source_name": "Stock Titan", "published_at": "2026-07-13T14:45:45", "published_display": "13 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$1.50-a-share windfall: Cumberland Pharma tags July 23 to qualify", "summary": "Cumberland Pharmaceuticals (CPIX) has declared a special cash dividend of $1.50 per share, payable on July 31, 2026, to shareholders of record on July 23, 2026. This dividend follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash u", "url": "https://www.stocktitan.net/news/CPIX/c-o-r-r-e-c-t-i-o-n-cumberland-pharmaceuticals-ahnq9l6s5fk2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T14:40:38", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 88, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Announces Special Dividend, Payable on July 31, 2026", "summary": "Cumberland Pharmaceuticals Inc. has declared a special cash dividend of $1.50 per share of its common stock. This dividend will be payable on July 31, 2026, to shareholders who are on record as of the close of business on July 10, 2026. This announcement comes amidst other compan", "url": "https://www.marketscreener.com/news/cumberland-pharmaceuticals-announces-special-dividend-payable-on-july-31-2026-ce7f5edcdb88f124", "source_name": "www.marketscreener.com", "published_at": "2026-07-13T12:35:00", "published_display": "13 Jul 2026 12:35", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Sees Modest Decline, Tests Key Support Zone - Percent Above MA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeUhWWXRyNzQyTkpjSHMwSFUxOHNXZ0otM0pneTFtaWpPYXU4U2twMHo0QVptZ1A1Q2NMQW53V3pURmlzSGY5dS1rVUE1UWZMNFdWUXRQTHB3OEpRZVRMRFlNR2FrQW93TTAwQnV2VWI2UEdtNlVELXk3UTk4V0hsdWpXTW5FN20weTd1X0hZcExieUlfMTRDaWNLbDl1c2RIMFdTVUFiVnljbzhMbHRrOWxaSWo0TWNF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T14:45:35+00:00", "published_display": "11 Jul 2026 14:45", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (Nasdaq:CPIX) - Stock Analysis", "summary": "Cumberland Pharmaceuticals Inc. (CPIX) recently saw Apotex Inc. complete the acquisition of certain assets related to pharmaceutical products for $100 million. Additionally, the company released updated positive results from its Phase 2 FIGHT DMD trial for ifetroban, a novel ther", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cpix/cumberland-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:41:44", "published_display": "06 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Sells Branded Drug Portfolio to Apotex for $100M, Refocuses on Rare Disease Pipeline 1", "summary": "Cumberland Pharmaceuticals Inc. has completed a $100 million cash transaction with Apotex Health Corp., selling its branded U.S. pharmaceuticals portfolio. This move allows Cumberland to refocus its resources on developing its rare disease pipeline, including clinical-stage progr", "url": "https://www.minichart.com.sg/2026/07/02/cumberland-pharmaceuticals-sells-branded-drug-portfolio-to-apotex-for-100m-refocuses-on-rare-disease-pipeline-1/", "source_name": "Minichart", "published_at": "2026-07-02T02:10:23", "published_display": "02 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals", "summary": "Apotex Health Corp., a major Canadian pharmaceutical company, has finalized its strategic transaction with Cumberland Pharmaceuticals Inc. This deal integrates Cumberland's U.S. branded businesses into Apotex. The announcement was made from Toronto on July 1, 2026.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/APTX-T/pressreleases/3077420/apotex-completes-previously-announced-strategic-transaction-with-cumberland-pharmaceuticals/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T01:12:12", "published_display": "02 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPIX - Cumberland Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a detailed financial overview of Cumberland Pharmaceuticals Inc. (CPIX). It includes key financial metrics, stock performance data, insider and institutional ownership, and valuation ratios, indicating a recent positive price chang", "url": "https://finviz.com/stock?t=CPIX&ta=0&p=m&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T23:10:23", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex", "summary": "Cumberland Pharmaceuticals announced the closing of a $100 million strategic transaction with Apotex, involving Apotex's acquisition of Cumberland's branded pharmaceutical line. This deal, strongly supported by shareholders, strengthens Cumberland's financial position, allowing i", "url": "https://finance.yahoo.com/healthcare/articles/cumberland-pharmaceuticals-closes-strategic-transaction-130000998.html", "source_name": "Market source", "published_at": "2026-07-01T23:09:26", "published_display": "01 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland (CPIX) nets $100M from Apotex deal, shifts to rare disease pipeline", "summary": "Cumberland Pharmaceuticals (CPIX) has completed the sale of its FDA-approved branded products to affiliates of Apotex for $100 million in cash. This strategic transaction significantly strengthens Cumberland's financial position, increasing its pro forma cash and cash equivalents", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-68b23e4a6f42.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:26", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals closes $100 million sale of drug portfolio", "summary": "Cumberland Pharmaceuticals has successfully closed a $100 million deal to sell a portion of its business to Apotex. This strategic move will allow Cumberland to refocus its operations. The article hints at the future direction of the Nashville-based firm following this significan", "url": "https://www.bizjournals.com/nashville/news/2026/07/01/cumberland-pharmaceuticals-closes-apotex-deal.html", "source_name": "The Business Journals", "published_at": "2026-07-01T19:09:26", "published_display": "01 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland sells branded drug portfolio to Apotex for $100m", "summary": "Cumberland Pharmaceuticals Inc. has sold its branded pharmaceutical products line to Apotex Health Corp. for $100 million in cash, following broad shareholder approval. This move allows Cumberland to strengthen its financial position and focus on developing its pipeline programs,", "url": "https://www.investing.com/news/company-news/cumberland-sells-branded-drug-portfolio-to-apotex-for-100m-93CH-4770611", "source_name": "Investing.com", "published_at": "2026-07-01T14:09:26", "published_display": "01 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland sells branded U.S. drugs to Apotex for $100M", "summary": "Cumberland Pharmaceuticals (CPIX) has closed a $100 million cash transaction with an Apotex subsidiary, selling its branded U.S. pharmaceutical line after securing over 99% shareholder approval. The company will now concentrate its resources on developing ifetroban, a compound wi", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-closes-strategic-transaction-with-3rz9x4hgf636.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:09:26", "published_display": "01 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference", "summary": "Cumberland Pharmaceuticals presented updated results from its Phase 2 FIGHT DMD trial for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy conference. The findings reinforced ifetroban's cardiopro", "url": "https://ca.finance.yahoo.com/news/cumberland-pharmaceuticals-shares-updated-fight-150000318.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-27T09:40:49", "published_display": "27 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data", "summary": "Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported positive updates from its Phase 2 FIGHT DMD trial for ifetroban, investigating its use in Duchenne muscular dystrophy (DMD) heart disease. The trial showed significant cardioprotective effects, including improved left ventri", "url": "https://www.sahmcapital.com/news/content/cumberland-pharma-advances-duchenne-program-with-new-safety-efficacy-data-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-26T22:11:28", "published_display": "26 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cumberland Pharma Stock Gaining Friday? - Cumberland Pharma (NASDAQ:CPIX)", "summary": "Cumberland Pharmaceuticals' stock (NASDAQ: CPIX) surged on Friday due to positive updates from its Phase 2 FIGHT DMD trial for ifetroban, a treatment for Duchenne muscular dystrophy (DMD) heart disease. The trial showed that ifetroban has cardioprotective effects, significantly i", "url": "https://www.benzinga.com/news/health-care/26/06/60136501/cumberland-pharma-advances-duchenne-program-with-new-safety-efficacy-data", "source_name": "Benzinga", "published_at": "2026-06-26T17:40:39", "published_display": "26 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Says Updated Data Support Ifetroban in Duchenne Muscular Dystrophy Cardiomyopathy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cumberland-says-updated-data-support-160406340.html", "source_name": "MT Newswires", "published_at": "2026-06-26T16:04:06+00:00", "published_display": "26 Jun 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland says updated DMD heart data strengthen ifetroban case", "summary": "Cumberland Pharmaceuticals (NASDAQ: CPIX) presented updated Phase 2 FIGHT DMD trial results for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the 2026 Parent Project Muscular Dystrophy conference. The data show that high-dose ifetroban le", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-shares-updated-fight-dmd-trial-results-at-tf0g5zb4jvp2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T14:40:39", "published_display": "26 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back Cumberland (NASDAQ: CPIX) sale of most assets", "summary": "Cumberland Pharmaceuticals Inc. shareholders have approved the sale of most of the company's assets to Apotex Inc. This strategic transaction, which includes FDA-approved commercial products, was overwhelmingly supported with 70.03% of all outstanding shares voting in favor. The ", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-52dcf3a95036.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:12:28", "published_display": "25 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cumberland Pharmaceuticals Inc (CPIX), highlighting its current earnings forecast score of 6.00, which ranks 132 out of 157 in the Pharmaceuticals industry. Based on the analysis of one analyst, CPIX currently holds a \"Hold\" rating. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:30", "published_display": "18 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cumberland Pharmaceuticals Inc (CPIX), focusing on its price momentum, support and resistance levels, and key technical indicators. As of June 18, 2026, CPIX has a price momentum score of 6.92 and is trading between a resistance level", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:55", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Cumberland Pharmaceuticals Inc (CPIX) has a financial score of 7.48, ranking 114 out of 157 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 22.04% year-over-year, and its ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:37", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Institutional Confidence", "summary": "This article analyzes the institutional confidence score for Cumberland Pharmaceuticals Inc (CPIX), which currently stands at 3.00, ranking 94th in the Pharmaceuticals industry. Institutional shareholding proportion decreased by 30.06% quarter-over-quarter, with James Simons iden", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:30", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cumberland-pharmaceuticals-vanderbilt-health-report-135111254.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:51:11+00:00", "published_display": "02 Jun 2026 13:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Rises 2.84%: Support Holds as Stock Approaches Resistance - Trend Following Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN2FodkhoM0ZSUVRMbWZlV1J5cTFlRkVnRXhveG9udjY5T0hHWEJXbEViRFFwRmlMemFpMmc3aW82S2N6YUpnZkJ1bVhzc21qaVNTYTNNbmJxU29JalU0Rm1pS04wUE1ZbzlWbk9BWXBTaFdNbXJUb1lSWGpZUGp6VVVxMlZiSjZCVTdqQ3JfalhPeWo2bEs4U3Q2M1RYdkRWUG5CS3hzY25HTGtveDdMX1cxQ0huUzlGUG83TlpPemVQdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with Apotex", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNGd6dlQ1TUVrTG9rS0wya3pLTUk2cHNsMUlkUGYwbVNabjRGYzZtRmw1dHZpWXZ4VkFGZlAyQUJoS29jaVZQT2VoS2xpSDJLeTNkcGdwVDZLaG9oUURPVG9ldkhXSU5maGpsWHNqUk9jRVAweE1qYkVpblQ3U01yVUNhaTBfckxIcVdISHBxYk5heDY5YjJ3UDJ0dlVyX29EZVlaZUlCMEh4OVlPeWV3dGZ3S25WWjcwWHNpQlBEcw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSzhHeGo4TXhtWUVER0xVVXktRkFEV29MbXN3cVVMTlJqZ280Vm1ldUdEUUpGZzc1elMxT21RTDZjOGFsTUdaR1h4S19Pblp5SUpDMFNGeC1ucTNWX3hYMktNbWJVOEJhdUpJNnBucDRfN0xwMW94WkR4SGdoVlMyaW53WmtIQ1ZOMnhmNFZPYUtEZzhBblVydDVJZ09rYmlISEVVbFRyckdLck5fS205TnRwZmlEVmNmdjJhY21YTWJmbjZZVThLZnBFZlRZanV5czdCM2FHTlZoQnBCU0trd1ZDWjhwRi1YdVRyMU9LWnFsY2VmU2xkZ2swbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals stock soars on $100M Apotex deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZHVnYkszZHg4ZDhCV0kyZVZ4dWpMNGZub2Zvb1FpaTFmbThrTXNCWVBkNzUtM3E3TjF2OEE3TllyNGo4VXVlaUtiX25OWnR2VjRHWXo3VURDSjRuWENVNzBFWVQ2M2V0TTMxSFNsaEZEdGRkcERucURzREx2UVk4WWpOZmJiWUtKZWxCaVY5WXQ4OUxJX3liYmFMZ3lsQ2l0MXhDWEdjWEZCbFVrYXJqbW85Z3lQWWR4eUc5MA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals sells drug portfolio for $100M to Canadian giant", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQYkZ0blBQaGNBSlhuS3lMcmlkRklBWlhxR3JIckltaVZUS3BsS0c5WjNXdXR2bDR6bVRNeU9mNXAzT3Q1TEdhM21NZF9RYzNqZHNfaGI1b0JfR211VDRLRHJiUHdqSUwwNTJCSW1EcnVOQWt6ZC1RSV9TZTZjTkJ5Sjc4QW1MX3NESS1aelZWdlY3U3U2bG05Q2hnaWduZ0w4WTZ1S2t3?oc=5", "source_name": "The Business Journals", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals jumps on $100M Apotex transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPWG1vMWlwa2JCRmlDSG1jZDhFSkZQYldjWk5lOFNHMks3SmJtODBSOF9LWEVHOFF0WXlwd18yeFNUUWYwLVJvaG1xY0NMajEzSGZTNUZjcUJBVTdsVUxwZFBBYlpaVlYxTmFxUGMwZ1d1MElVTUNHeTFYd3VtSXFjNzhybWpTUC1VcHdORWc2TWZzTFlfcGxaUF9XWXZkcWI5S0JJaHF6Mnl4YlhaRnF3WWRVWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland takes $100M cash deal, keeps three Phase II programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYVIybS1UZWtLYlpUbEtlZGhrQnhGVzJSdnVUU29kYnZuZ1pCRjlvTzZHUGtTZERNRzJZSFZKSEcycklHZGpVaDBVQm9IZndIbDVOOG9HWFBwejVfMHpULUZzdmxuTHY0a3dvTFc1dWR1VVhyM2tIRmpnNF9wLWotdXozcU1ZNkg0dFllZktQX051Tk9Pd2diSkZ0SDlYamlGX2g5cTZKME01WUFQanFpM0U3OElfblk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) jumps on $100 million Apotex asset-sale deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVjk1dzdpY195YldvLVNoSFZ2TVJHU01JNlgxQXZYcmNpZHlvZlU0RWhuYjktMmptQ2t5WWhRN2RlZ1hvdXFtclhmTE54RnlSeGhQTzFlTVItc1BmbVA1ZUlFX0cwNVlDT05taWM1bHpjZjhIY011VUwySGJkUmpfXzlIVG9WV01nMjlnejNVSFhQTVVQemVvbGRqa2lSLW1NbW1Ccm5rYmJmVUJxc2lkeQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Leads 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNeWg2Ql81aGxqWVVJZHEwSC1rUXdETmNVaUZET0FiSFdNU1NoVWtIaE5LLWpmOEVZcnJyeFVIMVRBaERkZHFwa1VSdVZZSEVkeWx0T3diQ3p3UGR0RlFkYklwdkF6aUVZWWRFRHdqOVpLSUZUTmpzU2hIYkstMi1naVBuR2lXcjRwLWZXVWNBVDNQUlUt?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNSE1VZXFTVWV3bjdCWGdVYmFEOHRaTDRQWUdxTW1qRGtzTmVkempCQUppeVE4OEZlOWRjQWJITEYtNml5M2lmOWVJV2hqRUh2X05IeVhKaENrdUd4b2tLRFpMb3ZZSnhmcVI5U1BCbnJTcW83VG1STWd0NXdGVEZUT2NacVo5U2JiNkVOR043bw?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cumberland Pharmaceuticals declares $1.50 special dividend, $5M buyback after $100M Apotex deal", "summary": "Cumberland Pharmaceuticals (CPIX) announced a special cash dividend of $1.50 per share and a new $5 million share repurchase program. These actions follow the closing of a $100 million strategic transaction with Apotex, which provided additional net cash. The company stated that ", "url": "https://www.tradingview.com/news/tradingview:9ee27ebfda661:0-cumberland-pharmaceuticals-declares-1-50-special-dividend-5m-buyback-after-100m-apotex-deal/", "source_name": "TradingView", "published_at": "2026-07-14T03:34:38", "published_display": "14 Jul 2026 03:34", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals 8-K Filing July 2026: Key Company Details, Stock Info, and Address on NASDAQ CPIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPcndoQkNIMWdfV0pIU0lJMnJHOF91Q3dHZ2w5WnNMeG82aVh1aHlkTTgtM2hkNXMtSDJhNEotbTFzUWJZeURFSDROaTJEWUNObTZGWnNsanRZZmZzbnZkM1lKSTZqR0s1d0V3VzloLVo2bUZxZDJ1czUzZUdIcThMTEZER2RNTEdVNlJqWDFQdlVHeDY3QWRqQ3UzaFJSbWE0bENEWlBiVTgxa3ZJLURBNGZBNFRsckt0dG5qTjlPQ09fS2JtZmV1NmtHU041UG9meGpUeUI5WDBuV0tvZWhJ?oc=5", "source_name": "Minichart", "published_at": "2026-07-14T00:44:00+00:00", "published_display": "14 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (Nasdaq: CPIX) returns cash after $100M Apotex deal", "summary": "Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share and authorized a new $5 million share repurchase program. These actions follow the company's strategic transaction with Apotex Health Corp., which brought in $100 million in cash at closing and ", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-52aff2944a9f.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:40:38", "published_display": "13 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals declares $1.50 dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZm5hUTBiTXpNWnlQTks0Q3Y3UnpacTA1ZUJsYmdHTkxTdEVGVzBWZDJGN0FIU2d5TmlWMjQxR2xtV3F3MF9BZGxOUGNDMkpfM3ZrYlJraVlGZWU1ZmhudFNyT1J3SHB2X19qVXNJZmN5MUcxYmdwS0QxcGo2SkFPbG1UUmczS2tjNW01UC0wcnNNZVVuWjFUVVMtdDlhNDFGbTBkUzJyNHpKZw?oc=5", "source_name": "MSN", "published_at": "2026-07-13T20:35:26+00:00", "published_display": "13 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX", "summary": "Cumberland Pharmaceuticals Inc.'s board of directors has authorized and declared a special cash dividend of $1.50 per share of common stock. This dividend will be payable on August 9, 2026, to shareholders of record as of July 26, 2026. The special dividend reflects the company's", "url": "https://www.moomoo.com/news/post/72869066/cumberland-pharma-board-of-directors-has-authorized-and-declared-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T16:40:38", "published_display": "13 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Declares Special Dividend, Approves $5 Million Share Buyback", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cumberland-declares-special-dividend-approves-152645804.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:26:45+00:00", "published_display": "13 Jul 2026 15:26", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQNmJSMWJJOTBUVTRrYnlXc0YxUEcxWGtfdjVjMy1jUnlwR0sxLWhEc3UxSU03X0NRQVpzcGNySjVERUFXWFIyM25YYWljeTVQdWQ2b0ROZDlPa1FlOGtiWkdfWURRb3ZMXzhwZlRWNlVkckRySHZQU0VxM2dmbU1HWkNPYlpjQkk3NFhNMEctSGV0NWdrM25sc2NRM212eXMzN0ctc1ViaHZXcXJtTU1YLVdVa2w?oc=5", "source_name": "Market source", "published_at": "2026-07-13T15:20:00+00:00", "published_display": "13 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE", "summary": "Cumberland Pharmaceuticals has announced a special cash dividend of $1.50 per common share. This dividend is payable to shareholders of record as of July 29, 2026, with the payment scheduled for August 12, 2026. This announcement highlights the company's financial performance and", "url": "https://www.moomoo.com/news/post/72869053/press-release-cumberland-pharmaceuticals-announces-special-dividend-of-1-50?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:40:38", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced a special cash dividend of $1.50 per share following a strategic transaction with Apotex Health. The dividend will be payable on July 31, 2026, to shareholders of record on July 10, 2026. This decision, along with a $5 mill", "url": "https://www.tradingview.com/news/prnewswire:cf16d7aeb8911:0-cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-share/", "source_name": "TradingView", "published_at": "2026-07-13T14:45:45", "published_display": "13 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$1.50-a-share cash windfall as Cumberland pivots to rare-disease drug ifetroban", "summary": "Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026, following a strategic transaction with Apotex Health that provided $100 million in cash. The company also authorized a $5 million share repurchase program and will red", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-zx3mc7ddqelp.html", "source_name": "Stock Titan", "published_at": "2026-07-13T14:45:45", "published_display": "13 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$1.50-a-share windfall: Cumberland Pharma tags July 23 to qualify", "summary": "Cumberland Pharmaceuticals (CPIX) has declared a special cash dividend of $1.50 per share, payable on July 31, 2026, to shareholders of record on July 23, 2026. This dividend follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash u", "url": "https://www.stocktitan.net/news/CPIX/c-o-r-r-e-c-t-i-o-n-cumberland-pharmaceuticals-ahnq9l6s5fk2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T14:40:38", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 88, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Announces Special Dividend, Payable on July 31, 2026", "summary": "Cumberland Pharmaceuticals Inc. has declared a special cash dividend of $1.50 per share of its common stock. This dividend will be payable on July 31, 2026, to shareholders who are on record as of the close of business on July 10, 2026. This announcement comes amidst other compan", "url": "https://www.marketscreener.com/news/cumberland-pharmaceuticals-announces-special-dividend-payable-on-july-31-2026-ce7f5edcdb88f124", "source_name": "www.marketscreener.com", "published_at": "2026-07-13T12:35:00", "published_display": "13 Jul 2026 12:35", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Sees Modest Decline, Tests Key Support Zone - Percent Above MA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeUhWWXRyNzQyTkpjSHMwSFUxOHNXZ0otM0pneTFtaWpPYXU4U2twMHo0QVptZ1A1Q2NMQW53V3pURmlzSGY5dS1rVUE1UWZMNFdWUXRQTHB3OEpRZVRMRFlNR2FrQW93TTAwQnV2VWI2UEdtNlVELXk3UTk4V0hsdWpXTW5FN20weTd1X0hZcExieUlfMTRDaWNLbDl1c2RIMFdTVUFiVnljbzhMbHRrOWxaSWo0TWNF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T14:45:35+00:00", "published_display": "11 Jul 2026 14:45", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (Nasdaq:CPIX) - Stock Analysis", "summary": "Cumberland Pharmaceuticals Inc. (CPIX) recently saw Apotex Inc. complete the acquisition of certain assets related to pharmaceutical products for $100 million. Additionally, the company released updated positive results from its Phase 2 FIGHT DMD trial for ifetroban, a novel ther", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cpix/cumberland-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:41:44", "published_display": "06 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Sells Branded Drug Portfolio to Apotex for $100M, Refocuses on Rare Disease Pipeline 1", "summary": "Cumberland Pharmaceuticals Inc. has completed a $100 million cash transaction with Apotex Health Corp., selling its branded U.S. pharmaceuticals portfolio. This move allows Cumberland to refocus its resources on developing its rare disease pipeline, including clinical-stage progr", "url": "https://www.minichart.com.sg/2026/07/02/cumberland-pharmaceuticals-sells-branded-drug-portfolio-to-apotex-for-100m-refocuses-on-rare-disease-pipeline-1/", "source_name": "Minichart", "published_at": "2026-07-02T02:10:23", "published_display": "02 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals", "summary": "Apotex Health Corp., a major Canadian pharmaceutical company, has finalized its strategic transaction with Cumberland Pharmaceuticals Inc. This deal integrates Cumberland's U.S. branded businesses into Apotex. The announcement was made from Toronto on July 1, 2026.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/APTX-T/pressreleases/3077420/apotex-completes-previously-announced-strategic-transaction-with-cumberland-pharmaceuticals/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T01:12:12", "published_display": "02 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPIX - Cumberland Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a detailed financial overview of Cumberland Pharmaceuticals Inc. (CPIX). It includes key financial metrics, stock performance data, insider and institutional ownership, and valuation ratios, indicating a recent positive price chang", "url": "https://finviz.com/stock?t=CPIX&ta=0&p=m&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T23:10:23", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex", "summary": "Cumberland Pharmaceuticals announced the closing of a $100 million strategic transaction with Apotex, involving Apotex's acquisition of Cumberland's branded pharmaceutical line. This deal, strongly supported by shareholders, strengthens Cumberland's financial position, allowing i", "url": "https://finance.yahoo.com/healthcare/articles/cumberland-pharmaceuticals-closes-strategic-transaction-130000998.html", "source_name": "Market source", "published_at": "2026-07-01T23:09:26", "published_display": "01 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland (CPIX) nets $100M from Apotex deal, shifts to rare disease pipeline", "summary": "Cumberland Pharmaceuticals (CPIX) has completed the sale of its FDA-approved branded products to affiliates of Apotex for $100 million in cash. This strategic transaction significantly strengthens Cumberland's financial position, increasing its pro forma cash and cash equivalents", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-68b23e4a6f42.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:26", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals closes $100 million sale of drug portfolio", "summary": "Cumberland Pharmaceuticals has successfully closed a $100 million deal to sell a portion of its business to Apotex. This strategic move will allow Cumberland to refocus its operations. The article hints at the future direction of the Nashville-based firm following this significan", "url": "https://www.bizjournals.com/nashville/news/2026/07/01/cumberland-pharmaceuticals-closes-apotex-deal.html", "source_name": "The Business Journals", "published_at": "2026-07-01T19:09:26", "published_display": "01 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland sells branded drug portfolio to Apotex for $100m", "summary": "Cumberland Pharmaceuticals Inc. has sold its branded pharmaceutical products line to Apotex Health Corp. for $100 million in cash, following broad shareholder approval. This move allows Cumberland to strengthen its financial position and focus on developing its pipeline programs,", "url": "https://www.investing.com/news/company-news/cumberland-sells-branded-drug-portfolio-to-apotex-for-100m-93CH-4770611", "source_name": "Investing.com", "published_at": "2026-07-01T14:09:26", "published_display": "01 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland sells branded U.S. drugs to Apotex for $100M", "summary": "Cumberland Pharmaceuticals (CPIX) has closed a $100 million cash transaction with an Apotex subsidiary, selling its branded U.S. pharmaceutical line after securing over 99% shareholder approval. The company will now concentrate its resources on developing ifetroban, a compound wi", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-closes-strategic-transaction-with-3rz9x4hgf636.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:09:26", "published_display": "01 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference", "summary": "Cumberland Pharmaceuticals presented updated results from its Phase 2 FIGHT DMD trial for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy conference. The findings reinforced ifetroban's cardiopro", "url": "https://ca.finance.yahoo.com/news/cumberland-pharmaceuticals-shares-updated-fight-150000318.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-27T09:40:49", "published_display": "27 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data", "summary": "Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported positive updates from its Phase 2 FIGHT DMD trial for ifetroban, investigating its use in Duchenne muscular dystrophy (DMD) heart disease. The trial showed significant cardioprotective effects, including improved left ventri", "url": "https://www.sahmcapital.com/news/content/cumberland-pharma-advances-duchenne-program-with-new-safety-efficacy-data-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-26T22:11:28", "published_display": "26 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cumberland Pharma Stock Gaining Friday? - Cumberland Pharma (NASDAQ:CPIX)", "summary": "Cumberland Pharmaceuticals' stock (NASDAQ: CPIX) surged on Friday due to positive updates from its Phase 2 FIGHT DMD trial for ifetroban, a treatment for Duchenne muscular dystrophy (DMD) heart disease. The trial showed that ifetroban has cardioprotective effects, significantly i", "url": "https://www.benzinga.com/news/health-care/26/06/60136501/cumberland-pharma-advances-duchenne-program-with-new-safety-efficacy-data", "source_name": "Benzinga", "published_at": "2026-06-26T17:40:39", "published_display": "26 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Says Updated Data Support Ifetroban in Duchenne Muscular Dystrophy Cardiomyopathy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cumberland-says-updated-data-support-160406340.html", "source_name": "MT Newswires", "published_at": "2026-06-26T16:04:06+00:00", "published_display": "26 Jun 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland says updated DMD heart data strengthen ifetroban case", "summary": "Cumberland Pharmaceuticals (NASDAQ: CPIX) presented updated Phase 2 FIGHT DMD trial results for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the 2026 Parent Project Muscular Dystrophy conference. The data show that high-dose ifetroban le", "url": "https://www.stocktitan.net/news/CPIX/cumberland-pharmaceuticals-shares-updated-fight-dmd-trial-results-at-tf0g5zb4jvp2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T14:40:39", "published_display": "26 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back Cumberland (NASDAQ: CPIX) sale of most assets", "summary": "Cumberland Pharmaceuticals Inc. shareholders have approved the sale of most of the company's assets to Apotex Inc. This strategic transaction, which includes FDA-approved commercial products, was overwhelmingly supported with 70.03% of all outstanding shares voting in favor. The ", "url": "https://www.stocktitan.net/sec-filings/CPIX/8-k-cumberland-pharmaceuticals-inc-reports-material-event-52dcf3a95036.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:12:28", "published_display": "25 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cumberland Pharmaceuticals Inc (CPIX), highlighting its current earnings forecast score of 6.00, which ranks 132 out of 157 in the Pharmaceuticals industry. Based on the analysis of one analyst, CPIX currently holds a \"Hold\" rating. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:30", "published_display": "18 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cumberland Pharmaceuticals Inc (CPIX), focusing on its price momentum, support and resistance levels, and key technical indicators. As of June 18, 2026, CPIX has a price momentum score of 6.92 and is trading between a resistance level", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:55", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Cumberland Pharmaceuticals Inc (CPIX) has a financial score of 7.48, ranking 114 out of 157 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 22.04% year-over-year, and its ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:37", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Inc (CPIX) Institutional Confidence", "summary": "This article analyzes the institutional confidence score for Cumberland Pharmaceuticals Inc (CPIX), which currently stands at 3.00, ranking 94th in the Pharmaceuticals industry. Institutional shareholding proportion decreased by 30.06% quarter-over-quarter, with James Simons iden", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cpix/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:30", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cumberland-pharmaceuticals-vanderbilt-health-report-135111254.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:51:11+00:00", "published_display": "02 Jun 2026 13:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Rises 2.84%: Support Holds as Stock Approaches Resistance - Trend Following Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN2FodkhoM0ZSUVRMbWZlV1J5cTFlRkVnRXhveG9udjY5T0hHWEJXbEViRFFwRmlMemFpMmc3aW82S2N6YUpnZkJ1bVhzc21qaVNTYTNNbmJxU29JalU0Rm1pS04wUE1ZbzlWbk9BWXBTaFdNbXJUb1lSWGpZUGp6VVVxMlZiSjZCVTdqQ3JfalhPeWo2bEs4U3Q2M1RYdkRWUG5CS3hzY25HTGtveDdMX1cxQ0huUzlGUG83TlpPemVQdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with Apotex", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNGd6dlQ1TUVrTG9rS0wya3pLTUk2cHNsMUlkUGYwbVNabjRGYzZtRmw1dHZpWXZ4VkFGZlAyQUJoS29jaVZQT2VoS2xpSDJLeTNkcGdwVDZLaG9oUURPVG9ldkhXSU5maGpsWHNqUk9jRVAweE1qYkVpblQ3U01yVUNhaTBfckxIcVdISHBxYk5heDY5YjJ3UDJ0dlVyX29EZVlaZUlCMEh4OVlPeWV3dGZ3S25WWjcwWHNpQlBEcw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSzhHeGo4TXhtWUVER0xVVXktRkFEV29MbXN3cVVMTlJqZ280Vm1ldUdEUUpGZzc1elMxT21RTDZjOGFsTUdaR1h4S19Pblp5SUpDMFNGeC1ucTNWX3hYMktNbWJVOEJhdUpJNnBucDRfN0xwMW94WkR4SGdoVlMyaW53WmtIQ1ZOMnhmNFZPYUtEZzhBblVydDVJZ09rYmlISEVVbFRyckdLck5fS205TnRwZmlEVmNmdjJhY21YTWJmbjZZVThLZnBFZlRZanV5czdCM2FHTlZoQnBCU0trd1ZDWjhwRi1YdVRyMU9LWnFsY2VmU2xkZ2swbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals stock soars on $100M Apotex deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZHVnYkszZHg4ZDhCV0kyZVZ4dWpMNGZub2Zvb1FpaTFmbThrTXNCWVBkNzUtM3E3TjF2OEE3TllyNGo4VXVlaUtiX25OWnR2VjRHWXo3VURDSjRuWENVNzBFWVQ2M2V0TTMxSFNsaEZEdGRkcERucURzREx2UVk4WWpOZmJiWUtKZWxCaVY5WXQ4OUxJX3liYmFMZ3lsQ2l0MXhDWEdjWEZCbFVrYXJqbW85Z3lQWWR4eUc5MA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals sells drug portfolio for $100M to Canadian giant", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQYkZ0blBQaGNBSlhuS3lMcmlkRklBWlhxR3JIckltaVZUS3BsS0c5WjNXdXR2bDR6bVRNeU9mNXAzT3Q1TEdhM21NZF9RYzNqZHNfaGI1b0JfR211VDRLRHJiUHdqSUwwNTJCSW1EcnVOQWt6ZC1RSV9TZTZjTkJ5Sjc4QW1MX3NESS1aelZWdlY3U3U2bG05Q2hnaWduZ0w4WTZ1S2t3?oc=5", "source_name": "The Business Journals", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals jumps on $100M Apotex transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPWG1vMWlwa2JCRmlDSG1jZDhFSkZQYldjWk5lOFNHMks3SmJtODBSOF9LWEVHOFF0WXlwd18yeFNUUWYwLVJvaG1xY0NMajEzSGZTNUZjcUJBVTdsVUxwZFBBYlpaVlYxTmFxUGMwZ1d1MElVTUNHeTFYd3VtSXFjNzhybWpTUC1VcHdORWc2TWZzTFlfcGxaUF9XWXZkcWI5S0JJaHF6Mnl4YlhaRnF3WWRVWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland takes $100M cash deal, keeps three Phase II programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYVIybS1UZWtLYlpUbEtlZGhrQnhGVzJSdnVUU29kYnZuZ1pCRjlvTzZHUGtTZERNRzJZSFZKSEcycklHZGpVaDBVQm9IZndIbDVOOG9HWFBwejVfMHpULUZzdmxuTHY0a3dvTFc1dWR1VVhyM2tIRmpnNF9wLWotdXozcU1ZNkg0dFllZktQX051Tk9Pd2diSkZ0SDlYamlGX2g5cTZKME01WUFQanFpM0U3OElfblk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals (CPIX) jumps on $100 million Apotex asset-sale deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVjk1dzdpY195YldvLVNoSFZ2TVJHU01JNlgxQXZYcmNpZHlvZlU0RWhuYjktMmptQ2t5WWhRN2RlZ1hvdXFtclhmTE54RnlSeGhQTzFlTVItc1BmbVA1ZUlFX0cwNVlDT05taWM1bHpjZjhIY011VUwySGJkUmpfXzlIVG9WV01nMjlnejNVSFhQTVVQemVvbGRqa2lSLW1NbW1Ccm5rYmJmVUJxc2lkeQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cumberland Pharmaceuticals Leads 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNeWg2Ql81aGxqWVVJZHEwSC1rUXdETmNVaUZET0FiSFdNU1NoVWtIaE5LLWpmOEVZcnJyeFVIMVRBaERkZHFwa1VSdVZZSEVkeWx0T3diQ3p3UGR0RlFkYklwdkF6aUVZWWRFRHdqOVpLSUZUTmpzU2hIYkstMi1naVBuR2lXcjRwLWZXVWNBVDNQUlUt?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNSE1VZXFTVWV3bjdCWGdVYmFEOHRaTDRQWUdxTW1qRGtzTmVkempCQUppeVE4OEZlOWRjQWJITEYtNml5M2lmOWVJV2hqRUh2X05IeVhKaENrdUd4b2tLRFpMb3ZZSnhmcVI5U1BCbnJTcW83VG1STWd0NXdGVEZUT2NacVo5U2JiNkVOR043bw?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 80, "total_relevant": 45, "sentiment_summary": {"positive": 21, "negative": 2, "neutral": 22, "score": 60, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "capital_return", "label": "Capital return", "weight": 6.05, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.93, "latest_week": "2026-07-10", "one_week_move": -6.9, "four_week_move": 5.9, "twelve_week_move": 83.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.977857, "market_dynamics_buy_signal": false, "relative_strength": 33.360046, "fair_value_gap": 107.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.0989, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, +5.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Minichart", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "dars.gov.et", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Capital return", "count": 11}, {"label": "Deals and strategy", "count": 8}, {"label": "Earnings", "count": 5}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.9% over one week, +5.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cumberland Pharmaceuticals declares $1.50 special dividend, $5M buyback after $100M Apotex deal"}], "updated_at": "2026-07-15T23:20:07.757264+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}